Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JCXH-105 vs Shingrix in Healthy Subjects ≥ 50 Years of Age
NCT06581575Phase 2Active, not recruiting
- Sponsor
- Immorna
- Start
- Oct 2024
- Primary completion
- Aug 2026
- Modality
- Nanoparticles, Vaccines & Immunotherapeutics, mRNA Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of JCXH-105 in herpes zoster (HZ), sponsored by Immorna. Started Oct 2024; status: active, not recruiting.
02
Drugs
JCXH-105
03
Conditions
herpes zoster (HZ)
Beyond the preview
Go deeper on NCT06581575.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06581575.